Verily aspires to create a world in which technology and life sciences are not distinct, but partners with a united mission. Formerly Google Life Sciences, Verily's mission is to bring together technology and life sciences to uncover new truths about health and disease. Verily's multidisciplinary teams have access to advanced research tools, large scale computing power, and unique technical expertise. They work with partners from across the industry and many fields of research to develop new technology, launch studies, and start companies.

Verily aspires to create a world in which technology and life sciences are not distinct, but partners with a united mission. Formerly Google Life Sciences, Verily's mission is to bring together technology and life sciences to uncover new truths about health and disease. Verily's multidisciplinary teams have access to advanced research tools, large scale computing power, and unique technical expertise. They work with partners from across the industry and many fields of research to develop new technology, launch studies, and start companies.

Healx integrates artificial intelligence with expert pharmacology to discover new treatments for rare diseases and to accelerate them into clinical trials within 2 years. To achieve this, Healx has developed the most comprehensive AI-based drug discovery platform for rare diseases: HealNet. HealNet disrupts the conventional process of drug discovery, reducing the costs, time and risk of bringing new therapies to market. Our plan is to have 100 treatments for rare diseases in development by 2025.

Healx integrates artificial intelligence with expert pharmacology to discover new treatments for rare diseases and to accelerate them into clinical trials within 2 years. To achieve this, Healx has developed the most comprehensive AI-based drug discovery platform for rare diseases: HealNet. HealNet disrupts the conventional process of drug discovery, reducing the costs, time and risk of bringing new therapies to market. Our plan is to have 100 treatments for rare diseases in development by 2025.